Life sciences is a vital industry in the Irish economy, and a key practice area for ByrneWallace.
Ranked as a top tier practice group by Legal 500, our dedicated Life Sciences team is led by Colin Sainsbury, who previously held senior in-house legal positions in the pharmaceutical and biotech industry and has extensive sectoral specific international commercial and regulatory experience.
Our team draws on the specialist skills and technical expertise of lawyers from a range of practice areas including corporate, capital markets, regulatory, intellectual property, healthcare and health services, employment, litigation, tax, product liability, EU and competition, property, projects and construction teams, as well as other specialist practice areas.
We pool our diverse and complementary skills in an integrated, practical and innovative manner according to client needs. This dynamic and flexible approach has enabled us to develop and maintain a leading position in the provision of focused advice to life sciences companies.
We advise all types of enterprises active in the life sciences industry. Our clients range from the earliest stage university spin-out companies to established publicly quoted indigenous companies and global pharmaceutical, biotech and medical device organisations. We also act for venture capital and private equity funds investing in the Irish life sciences industry, research institutions and companies involved in the establishment and provision of healthcare services.
Our specialist skill sets, together with real industry and regulatory experience and a dedicated approach to serving the life sciences industry, enables us to provide the highest quality legal service in a focused manner.
- Structuring and negotiation of complex transactions
- Life science and pharmaceutical regulatory law
- Conduct of clinical trials
- EU medicine law
- Sectoral specific competition law
- Research and development
- Intellectual property law
- Licensing and marketing of technologies and pharmaceutical products.
Please click here to read details of our recent assignments.
Chambers and Partners
"…the firm is also home to what is perhaps Ireland's leading life sciences practice".
"…the team was lauded for its capabilities in the technology and life sciences fields." In the corporate/M&A section Colin Sainsbury was described as "very commercial and pleasant to work with".
Colin is also recommended as a leading individual within the Intellectual Property section, described as "superb – his commercial acumen is unique among the lawyers we have dealt with".
"[the firm] has a sterling record for corporate work within the life sciences sector due to the respect afforded to Colin Sainsbury, a former pharmaceutical in-house counsel, who is ‘ sought after for his in-depth industry knowledge and experience’."
ByrneWallace advised Neuromod Devices in connection with an €8 million fundraising.
ByrneWallace advise Nuvo Pharmaceuticals (Ireland) DAC (Nuvo Ireland) in relation to its acquisition of a number of pharmaceutical assets, as part of the completion by Nuvo Pharmaceuticals Inc. (Nuvo) of the acquisition of Aralez Pharmaceuticals Inc.
ByrneWallace advise Inflazome Limited in relation to its €40 million Series B Financing to develop NLRP3 inflammasome inhibitors to clinical proof-of-concept.